Trending...
- Cruxy shortlisted for two Private Equity Wire® US Awards 2026: Advisory Firm of the Year (Overall) & Value Creation Consulting Firm of the Year
- Heritage at Manalapan Welcomes New Sales Team as Luxury Single-Family Home Community Continues to Grow
- Parents No Longer Have to Wait 3 Weeks for a Sleep Consultant: Nora Talks Tonight, Stays for 5 Days, Costs $89
ATLANTA, Aug. 7, 2024 ~ Huxley Medical, a leading developer of technologies that streamline cardiopulmonary care, has recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for their revolutionary sleep apnea diagnostic patch, SANSA. This groundbreaking device is worn on the chest and represents a significant breakthrough in medical innovation.
Unlike current sleep apnea diagnostic tools such as patches, rings, watches, or finger probes, SANSA does not require any additional attachments or wires. Its patented combination of sensors and materials allows for precise measurement of eight physiological channels including blood oxygen saturation, EKG-derived heart rate, respiratory effort, chest movement, sleep staging, snoring, body position, and actigraphy.
This FDA clearance is a major milestone for Huxley Medical and positions their SANSA device as the first and only FDA-cleared chest-worn patch that utilizes advanced signal processing and artificial intelligence to detect sleep disordered breathing while simultaneously providing an electrocardiogram (EKG) reference channel to record electrical signals from the heart.
Chris Hallett, co-founder and chief commercial officer of Huxley Medical with over 25 years of experience in the field, expressed excitement about this achievement. "Our SANSA technology offers healthcare providers a cutting-edge tool to enhance diagnostic accuracy and patient outcomes," he said. This announcement is just the latest in a series of milestones for Huxley Medical since its founding in 2019. The company has raised over $20 million in investment capital and grant funding.
More on ncarol.com
Sleep apnea is a serious disorder that affects millions of people worldwide. It is characterized by repeated interruptions in breathing during sleep which can leave patients feeling tired and irritable even after a full night's rest. If left untreated, it can lead to more serious health issues such as heart disease and strokes. According to the American Academy of Sleep Medicine, sleep apnea costs $86.9 billion in lost productivity, $26.2 billion in motor vehicle accidents, and $6.5 billion in workplace hazards in the U.S. each year.
Hallett, drawing from his prior experience developing programs to engage sleep physicians and cardiologists, understands the difficulties in getting patients with sleep apnea and comorbid arrhythmias diagnosed and managed. "SANSA will begin to eliminate these barriers for physicians and patients," he said.
The SANSA platform has already undergone a comprehensive clinical trial involving 533 patients across seven U.S. sites, including prestigious institutions such as the University of Pennsylvania, the University of Michigan, Emory University, and Atrium Health Wake Forest Baptist. The results of this trial have demonstrated SANSA's efficacy in measurement reliability and performance for diagnosing mild, moderate, and severe sleep apnea.
The clinical trial also provided robust data supporting SANSA's safety and effectiveness, including its high accuracy, sensitivity, and specificity in detecting sleep apnea compared to traditional in-lab sleep tests. Additionally, patients reported improved compliance and comfort due to its non-invasive nature. One of the most significant achievements of SANSA is its ability to perform well on all skin tones for diverse patient management – a challenge that has been faced by previous diagnostic tools.
More on ncarol.com
Clinicians who have utilized the SANSA device have praised it as a milestone in innovation. Dr. Suneet Mittal, Chair of Valley Health System's Cardiovascular Service Line as well as director of electrophysiology said, "As electrophysiologists, we are already quite comfortable using patch-based EKG monitors for arrhythmia monitoring." He added that "the ability to diagnose sleep apnea using the same platform using the SANSA device represents an exciting opportunity to manage two diseases that often co-exist."
Dr. Douglas Kirsch, past president of the American Academy of Sleep Medicine and medical director of Atrium Health Sleep Medicine in Charlotte, N.C., also shared his enthusiasm for SANSA. "It's excellent news for the sleep community that Huxley's SANSA device has been cleared by the FDA to evaluate obstructive sleep apnea at all severity levels with reliable performance across all skin tones," he said. "This 8-channel wearable patch, including an EKG sensor, should be easy for patient self-application and improve the experience for diagnosis of obstructive sleep apnea."
With this FDA clearance, Huxley Medical can now move forward to market their SANSA device and provide healthcare providers with a cutting-edge tool to enhance diagnostic accuracy and improve patient outcomes. This groundbreaking technology has the potential to revolutionize the way sleep apnea is diagnosed and managed, providing a more comfortable and accurate experience for patients.
Unlike current sleep apnea diagnostic tools such as patches, rings, watches, or finger probes, SANSA does not require any additional attachments or wires. Its patented combination of sensors and materials allows for precise measurement of eight physiological channels including blood oxygen saturation, EKG-derived heart rate, respiratory effort, chest movement, sleep staging, snoring, body position, and actigraphy.
This FDA clearance is a major milestone for Huxley Medical and positions their SANSA device as the first and only FDA-cleared chest-worn patch that utilizes advanced signal processing and artificial intelligence to detect sleep disordered breathing while simultaneously providing an electrocardiogram (EKG) reference channel to record electrical signals from the heart.
Chris Hallett, co-founder and chief commercial officer of Huxley Medical with over 25 years of experience in the field, expressed excitement about this achievement. "Our SANSA technology offers healthcare providers a cutting-edge tool to enhance diagnostic accuracy and patient outcomes," he said. This announcement is just the latest in a series of milestones for Huxley Medical since its founding in 2019. The company has raised over $20 million in investment capital and grant funding.
More on ncarol.com
- Kerri Lawless Introduces New Home-Selling Option for Local Homeowners
- As Boone Takes Art to the Streets, KayeDinero Asks What Makes Creativity Human
- FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
- Baird Medical Turns Global Expansion Into Tangible Growth: N A S D A Q: BDMD Posts 25% Revenue Surge as U.S. and International Markets Accelerate
- Black Mountain Meets "Human Error": KayeDinero on What Technology Can't Reproduce
Sleep apnea is a serious disorder that affects millions of people worldwide. It is characterized by repeated interruptions in breathing during sleep which can leave patients feeling tired and irritable even after a full night's rest. If left untreated, it can lead to more serious health issues such as heart disease and strokes. According to the American Academy of Sleep Medicine, sleep apnea costs $86.9 billion in lost productivity, $26.2 billion in motor vehicle accidents, and $6.5 billion in workplace hazards in the U.S. each year.
Hallett, drawing from his prior experience developing programs to engage sleep physicians and cardiologists, understands the difficulties in getting patients with sleep apnea and comorbid arrhythmias diagnosed and managed. "SANSA will begin to eliminate these barriers for physicians and patients," he said.
The SANSA platform has already undergone a comprehensive clinical trial involving 533 patients across seven U.S. sites, including prestigious institutions such as the University of Pennsylvania, the University of Michigan, Emory University, and Atrium Health Wake Forest Baptist. The results of this trial have demonstrated SANSA's efficacy in measurement reliability and performance for diagnosing mild, moderate, and severe sleep apnea.
The clinical trial also provided robust data supporting SANSA's safety and effectiveness, including its high accuracy, sensitivity, and specificity in detecting sleep apnea compared to traditional in-lab sleep tests. Additionally, patients reported improved compliance and comfort due to its non-invasive nature. One of the most significant achievements of SANSA is its ability to perform well on all skin tones for diverse patient management – a challenge that has been faced by previous diagnostic tools.
More on ncarol.com
- As Brevard Heads Into Mountain Song Weekend, KayeDinero Brings a Different Kind of WNC Sound
- Why Did KayeDinero Put Haywood Road Into a Song?
- Shelter Structures America makes European debut at TEMPOR EXPO 2026 in Fulda, Germany
- TekTone innovation meets patient care
- HydroExcavation.com Relaunches With Exclusive Local Service Areas and Dedicated Hydrovac Manufacturer Directory
Clinicians who have utilized the SANSA device have praised it as a milestone in innovation. Dr. Suneet Mittal, Chair of Valley Health System's Cardiovascular Service Line as well as director of electrophysiology said, "As electrophysiologists, we are already quite comfortable using patch-based EKG monitors for arrhythmia monitoring." He added that "the ability to diagnose sleep apnea using the same platform using the SANSA device represents an exciting opportunity to manage two diseases that often co-exist."
Dr. Douglas Kirsch, past president of the American Academy of Sleep Medicine and medical director of Atrium Health Sleep Medicine in Charlotte, N.C., also shared his enthusiasm for SANSA. "It's excellent news for the sleep community that Huxley's SANSA device has been cleared by the FDA to evaluate obstructive sleep apnea at all severity levels with reliable performance across all skin tones," he said. "This 8-channel wearable patch, including an EKG sensor, should be easy for patient self-application and improve the experience for diagnosis of obstructive sleep apnea."
With this FDA clearance, Huxley Medical can now move forward to market their SANSA device and provide healthcare providers with a cutting-edge tool to enhance diagnostic accuracy and improve patient outcomes. This groundbreaking technology has the potential to revolutionize the way sleep apnea is diagnosed and managed, providing a more comfortable and accurate experience for patients.
0 Comments
Latest on ncarol.com
- Qscription Technologies and NEOPATHOLOGY CORP. Sign MOU to Bring FDA-Cleared Lung Imaging AI into U.S. Clinical Practice
- Asheville Artist KayeDinero Asks What Happens When Technology Gets Too Human on "Human Error"
- Heritage at Manalapan Welcomes New Sales Team as Luxury Single-Family Home Community Continues to Grow
- Mandeville Pests May Pose Serious Health Risks for Your Family
- TOLI North America's Floorleum Plain AdVantage Transforms Flooring Into a Wayfinding Tool
- Share your workplace safety solutions at 2027 Applied Ergonomics Conference
- Parents No Longer Have to Wait 3 Weeks for a Sleep Consultant: Nora Talks Tonight, Stays for 5 Days, Costs $89
- May The Worst Team Win! Loserball Kicks Off Another NFL Season of Hilarious Mayhem
- Black Women Living With, and Impacted by, HIV Express Gratitude, Grief, Joy, and Resilience
- MainConcept Easy Video API Extends Full Transcoding to Arm and NETINT VPUs
- From Detroit Streets to Blue Ridge Mountains: KayeDinero Finds a New Sound in Western North Carolina
- Why Did KayeDinero Name a Song After Hendersonville?
- Cruxy shortlisted for two Private Equity Wire® US Awards 2026: Advisory Firm of the Year (Overall) & Value Creation Consulting Firm of the Year
- Did Asheville's BoomTown Weekend Inspire KayeDinero's Next Move?
- From City Girl to Mountain Life: KayeDinero Releases "City Girl Saved" From Asheville
- Lake Norman Philharmonic - Free Community Concert
- Amaris Mint® Confirms UK Availability of Swedish-Made BioBoost Daily Nutrition Range
- Sea Tales Strengthens U.S. Leadership Team as Retail Expansion Accelerates
- Patented Foodservice Products Company with Strong Gross Margins and Substantial Two-Year Revenue Growth Hits Market for $1.6 Million
- Robert DeMaio, Phinge CEO to Speak at 30th IIPLA 2026 on Securing IP, User Data & Digital Sovereignty via Verified App-less Tech. Attend the Live Q&A!